BR112022019223A2 - Formulação de complexo de inclusão em ciclodextrina (cd), complexo de inclusão em ciclodextrina (cd), uso da formulação de complexo de inclusão em ciclodextrina (cd), uso de um veículo de entrega de um complexo de inclusão em ciclodextrina, método para o tratamento oral de uma disfunção, método para o tratamento oral de um humano, uso da composição, composição e método de tratamento de um transtorno das vias aéreas - Google Patents

Formulação de complexo de inclusão em ciclodextrina (cd), complexo de inclusão em ciclodextrina (cd), uso da formulação de complexo de inclusão em ciclodextrina (cd), uso de um veículo de entrega de um complexo de inclusão em ciclodextrina, método para o tratamento oral de uma disfunção, método para o tratamento oral de um humano, uso da composição, composição e método de tratamento de um transtorno das vias aéreas

Info

Publication number
BR112022019223A2
BR112022019223A2 BR112022019223A BR112022019223A BR112022019223A2 BR 112022019223 A2 BR112022019223 A2 BR 112022019223A2 BR 112022019223 A BR112022019223 A BR 112022019223A BR 112022019223 A BR112022019223 A BR 112022019223A BR 112022019223 A2 BR112022019223 A2 BR 112022019223A2
Authority
BR
Brazil
Prior art keywords
inclusion complex
cyclodextrin inclusion
cyclodextrin
treatment
formulation
Prior art date
Application number
BR112022019223A
Other languages
English (en)
Portuguese (pt)
Inventor
Czap Ai
Original Assignee
Czap Res And Development Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Czap Res And Development Llc filed Critical Czap Res And Development Llc
Publication of BR112022019223A2 publication Critical patent/BR112022019223A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
BR112022019223A 2020-03-23 2021-03-23 Formulação de complexo de inclusão em ciclodextrina (cd), complexo de inclusão em ciclodextrina (cd), uso da formulação de complexo de inclusão em ciclodextrina (cd), uso de um veículo de entrega de um complexo de inclusão em ciclodextrina, método para o tratamento oral de uma disfunção, método para o tratamento oral de um humano, uso da composição, composição e método de tratamento de um transtorno das vias aéreas BR112022019223A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062993346P 2020-03-23 2020-03-23
PCT/IB2021/052411 WO2021191803A1 (en) 2020-03-23 2021-03-23 Oral terpene cyclodextrin inclusion complex vehicles

Publications (1)

Publication Number Publication Date
BR112022019223A2 true BR112022019223A2 (pt) 2022-11-29

Family

ID=77890198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019223A BR112022019223A2 (pt) 2020-03-23 2021-03-23 Formulação de complexo de inclusão em ciclodextrina (cd), complexo de inclusão em ciclodextrina (cd), uso da formulação de complexo de inclusão em ciclodextrina (cd), uso de um veículo de entrega de um complexo de inclusão em ciclodextrina, método para o tratamento oral de uma disfunção, método para o tratamento oral de um humano, uso da composição, composição e método de tratamento de um transtorno das vias aéreas

Country Status (10)

Country Link
US (1) US20230142208A1 (cg-RX-API-DMAC7.html)
EP (2) EP4653002A3 (cg-RX-API-DMAC7.html)
JP (1) JP7758353B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220156931A (cg-RX-API-DMAC7.html)
CN (2) CN120037401A (cg-RX-API-DMAC7.html)
AU (1) AU2021240473B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019223A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170465A1 (cg-RX-API-DMAC7.html)
IL (1) IL296661B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021191803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4380556A4 (en) * 2021-08-04 2025-07-02 Czap Res And Development Llc ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES
CN116270589B (zh) * 2023-02-08 2024-05-31 北京奥秘佳得医药科技有限公司 药物组合物和化合物在制备用于治疗疾病的药物中的用途
CN117357556B (zh) * 2023-11-06 2024-04-19 广州市生基科技有限公司 一种高稳定性的氧胶囊的制备方法
WO2025229618A1 (en) * 2024-05-02 2025-11-06 Czap Research And Development, Llc Blood glucose control with enzymatic cyclodextrin inclusion complex formulations
WO2025238557A1 (en) * 2024-05-13 2025-11-20 Czap Research And Development, Llc Cholesterol control with enzymatic cyclodextrin inclusion complex formulations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199543A (en) 1981-01-23 1985-04-30 Wellcome Found Inclusion complexes of cyclodextrins and cardiac clycosides;pharmaceutical formulations
US4538920A (en) 1983-03-03 1985-09-03 Minnesota Mining And Manufacturing Company Static mixing device
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
HU201685B (en) * 1987-04-23 1990-12-28 Chinoin Gyogyszer Es Vegyeszet For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition
CA1321192C (en) 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
CN1232539C (zh) * 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
AU2003263162B2 (en) * 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
US7001893B2 (en) 2002-10-28 2006-02-21 Council Of Scientific And Industrial Research Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
CA2561660C (en) * 2004-04-01 2012-10-30 Universite De Liege Pharmaceutical compositions of pyrimidine-2,4,6-triones
WO2006058153A1 (en) 2004-11-23 2006-06-01 Smith & Nephew, Inc. Composite mixer
US20060120967A1 (en) * 2004-12-07 2006-06-08 Qpharma, Llc Solution forms of cyclodextrins for nasal or throat delivery of essential oils
US20090029020A1 (en) 2005-06-13 2009-01-29 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
RU2008101420A (ru) 2005-06-13 2009-07-20 Карджилл, Инкорпорейтед (Us) Циклодекстриновые комплексы включения и способы их получения
EP1746045B1 (de) 2005-07-22 2009-09-16 Dentaco Dentalindustrie- und Marketing GmbH Mehrkammerausgabevorrichtung
US20070072146A1 (en) 2005-09-29 2007-03-29 Dentsply Research And Development Corp. Dispensing syringe having multiple barrels for discharging a dental composition
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US8100295B2 (en) 2006-03-24 2012-01-24 Medmix Systems Ag Dispensing assembly with removably attachable accessories
EP1847181B1 (de) * 2006-04-19 2008-12-17 Symrise GmbH & Co. KG Neue Verwendungen von Nonenolid
CN100411688C (zh) 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
EP2178521B1 (en) 2007-07-11 2014-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
KR100929920B1 (ko) 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
WO2010070617A1 (en) * 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
KR101050429B1 (ko) * 2009-03-18 2011-07-19 연세대학교 산학협력단 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물
EP2444336B1 (de) 2010-10-21 2013-08-28 Sulzer Mixpac AG Doppel-Austragsvorrichtung
CA2886115A1 (en) 2012-10-02 2014-04-10 Allergan, Inc. Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes
US10098964B2 (en) * 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
US20170224841A1 (en) * 2016-02-04 2017-08-10 Czap Reseach And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
CN115154619B (zh) 2016-02-04 2025-11-28 西泽普研究与发展有限责任公司 受控释放和层状的环糊精包合物媒介物
US20170224842A1 (en) * 2016-02-04 2017-08-10 Czap Research And Development, Llc Controlled-release and stratified cyclodextrin inclusion complex vehicles
US20170087199A1 (en) * 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
IL279942B1 (en) * 2018-07-08 2026-08-01 Buzzelet Development And Tech Ltd Cannabinoid compositions from twenty terpenes for the male population
WO2020168421A1 (en) * 2019-02-19 2020-08-27 Agrima Scientific Corp. Cyclodextrin inclusion complexes of cannabis extracts
US11633351B2 (en) * 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets

Also Published As

Publication number Publication date
EP4125830B1 (en) 2025-10-15
EP4653002A2 (en) 2025-11-26
CN120037401A (zh) 2025-05-27
AU2021240473A1 (en) 2022-09-29
CA3170465A1 (en) 2021-09-30
JP7758353B2 (ja) 2025-10-22
CN115335040B (zh) 2025-01-21
EP4125830C0 (en) 2025-10-15
EP4125830A1 (en) 2023-02-08
WO2021191803A1 (en) 2021-09-30
KR20220156931A (ko) 2022-11-28
US20230142208A1 (en) 2023-05-11
AU2021240473B2 (en) 2026-05-28
CN115335040A (zh) 2022-11-11
EP4125830A4 (en) 2023-12-20
IL296661B2 (en) 2026-06-01
IL296661A (en) 2022-11-01
JP2023519232A (ja) 2023-05-10
IL296661B1 (en) 2026-02-01
EP4653002A3 (en) 2026-02-25

Similar Documents

Publication Publication Date Title
Ruutu et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study
EP4653002A3 (en) Oral terpene cyclodextrin inclusion complex vehicles
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
MX2008009357A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceuctica y un conjunto (kit) de dicha formulacion.
CU23821A3 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
BRPI0510771A (pt) agente de benefìcio que contém partìcula de distribuição
BRPI0512583A (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
NO20092616L (no) Antifolatmiddelkombinasjoner i behandling av kreft
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
BR112018001533A2 (pt) método de redução da necessidade de cirurgia em pacientes sofrendo da hiperplasia benigna da próstata
BRPI0810384B8 (pt) terapia enzimática anticâncer
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2020260956A3 (en) Self-emulsifying cannabidiol formulations
Ramos‐Junior et al. CD73‐dependent adenosine dampens interleukin‐1β–induced CXCL8 production in gingival fibroblasts: association with heme oxygenase‐1 and adenosine monophosphate‒activated protein kinase
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
Han et al. The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response
WO2012115247A1 (ja) 角層剥離促進剤
MX2018015893A (es) Compuestos anti-cancer.
AR021663A1 (es) Clatratos de dehidroepiandrosterona y composiciones farmaceuticas correspondientes

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]